Targeting Splicing in Prostate Cancer

Effrosyni Antonopoulou and Michael Ladomery *
Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Bristol BS16 1QY, UK; londinoantonopoulou@hotmail.com
* Correspondence: Michael.Ladomery@uwe.ac.uk; Tel.: +44-117-328-3531
Received: 12 March 2018; Accepted: 23 April 2018; Published: 25 April 2018

Abstract: Over 95% of human genes are alternatively spliced, expressing splice isoforms that often exhibit antagonistic functions. We describe genes whose alternative splicing has been linked to prostate cancer; namely VEGFA, KLF6, BCL2L2, ERG, and AR. We discuss opportunities to develop novel therapies that target specific splice isoforms, or that target the machinery of splicing. Therapeutic approaches include the development of small molecule inhibitors of splice factor kinases, splice isoform specific siRNAs, and splice switching oligonucleotides.

Keywords: alternative splicing; prostate cancer; VEGFA; KLF6; BCL2L2; ERG; AR; splice switching oligonucleotides; RNA interference; splice factors; splice factor kinases

1. Introduction

1.1. Pre-mRNA Splicing and Its Regulation

Pre-mRNA splicing was discovered in 1977 when the RNA sequence of adenoviruses was compared with their genome through the direct visualisation of RNA-DNA hybrids via electron microscopy. The hybrids of mRNA and restriction endonuclease cleavage fragments of viral DNA revealed loops that were unable to hybridize to the DNA. These intervening sequences were called ‘introns’ whereas the hybridized regions were called ‘exons’ [1,2].

Pre-mRNA splicing is catalysed by the spliceosome, a dynamic molecular machine which includes five small nuclear ribonucleoprotein particles (snRNPs) and a large number of auxiliary proteins [3]. These cooperate to recognize splice sites accurately and catalyse two transesterification reactions, each involving a nucleophilic attack on the terminal phosphodiester bonds of the intron [4]. Three sites participate in the splicing reaction: the 5′ splice site (5′ SS); the 3′ splice site (3′ SS); and the branch point sequence (BPS). It is now clear that the vast majority of human genes (>95%) are alternatively spliced, so that exons can be spliced together in different ways [5].

Pre-mRNA splicing is remarkably accurate thanks to the involvement of cis-regulatory elements that facilitate the identification of exon–intron junctions, preventing ‘pseudoxons’ from being included in mRNA. These elements can act as exonic splicing enhancers (ESEs) or silencers (ESSs), and intronic splicing enhancers (ISEs) or silencers (ISSs) [6,7]. They are recognised by ‘splice factors’, including RNA-binding proteins of the SR (serine/arginine-rich) family and the hnRNPs (heterogenous nuclear ribonucleoprotein) proteins [8]. SR proteins generally facilitate the recruitment of spliceosomal components such as the U1 snRNP to the 5′ splice site or U2AF65 to the pyrimidine tract adjacent to the 3′ splice site, facilitating recruitment of U2 snRNP across the branchpoint [9]. The SR protein SRSF1 binds to the ESE and facilitates splice site selection by promoting exon definition, helping to select alternative 5′ or 3′ splice sites in a concentration-dependent manner [10,11]. Increased concentrations of SRSF1 often promotes the selection of intron-proximal splice sites whereas increased concentrations of hnRNP A1 promotes that of intron-distal splice sites [12]. However, SR and hnRNP proteins can also do the opposite, depending on cell type [13,14].

Int. J. Mol. Sci. 2018, 19, 1287; doi:10.3390/ijms19051287 www.mdpi.com/journal/ijms
Several splice factors, including SR proteins, undergo post-translational modifications which influence their interaction and specificity with other proteins as well as their local concentration adjacent to pre-mRNA substrates [15,16]. These modifications include phosphorylation by protein kinases such as AKT [17,18], DYRKs [19,20], SRPKs, and CLKs [21–23], and dephosphorylation by protein phosphatases including PP1 and PP2 [24]. These modifications also regulate SR protein contributions to the regulation of mRNA export [25], nonsense-mediated decay [26], and mRNA translation [27].

1.2. Extent of Alternative Splicing

In 1978, Wally Gilbert proposed that different combinations of exons could produce multiple mRNA isoforms of a single gene introducing the concept of alternative splicing [28,29]. Alternative splicing is the main source of proteomic and functional diversity and is crucial for the correct expression of the majority of metazoan genes [6,7]. A widely cited example that illustrates the ability of alternative splicing to generate a substantial repertoire of proteins is the *Drosophila melanogaster* gene *Dscam* (Down syndrome cell adhesion molecule). It can express 38,016 distinct splice isoforms from several clusters of mutually exclusive exons [30]. The isoforms differ in the three IgG-like domains in the extracellular portion of Dscam, changing their binding specificity. The different binding specificities affect interactions between cells, facilitating complex networks of neuronal connections.

The neurexin genes are a well-studied family of genes in both invertebrates and vertebrates; they are required for the formation and function of synapses. They are highly diversified in vertebrates, and are also characterised by extensive alternative splicing through multiple mini-exons and alternative 5′ and 3′ splice sites producing an impressively wide range of splice isoforms [31]. Alternative splicing has been examined in the nematode model organism *Caenorhabditis elegans* demonstrating tissue-specific alternative splicing [32] and an involvement in sex determination [33]. Alternative splicing has also been documented in plants [34]; examples include alternative transcripts of *Vp-1* in wheat [35], and the *r1* gene [36] and the MADS box genes in maize [37].

There are several types of alternative splicing. The most prevalent type in vertebrates and invertebrates is exon skipping, in which whole exons are omitted from the mature transcript. Mutually exclusive exons are adjoining exons where only one is included in the mRNA. The boundaries and therefore sizes of exons can also vary through the use of alternative 5′ or alternative 3′ splice sites. Another form of alternative splicing is intron retention, in which individual introns are not removed. There are generally higher rates of intron retention in less complex metazoans [38]. The use of alternative exons can also arise due to alternative promoters or alternative polyadenylation sites. Nearly 95% of human genes are alternatively spliced expressing at least 90,000 isoforms from ~20,000 protein-coding genes [39]. Alternative splicing plays an important role in normal development and differentiation; aberrant alternative splicing is associated with an increasing range of human diseases including tauopathies, spinal muscular atrophy, retinitis pigmentosa, and many types of cancer [40,41]. Thus, understanding the nature and regulation of alternative splicing is a major topic in molecular biology nowadays. Its involvement in disease processes presents novel therapeutic opportunities.

2. Alternative Splicing and Prostate Cancer

2.1. The Challenge of Prostate Cancer

Prostate cancer (PCA) is one of the most important public health concerns worldwide with numbers of cases increasing significantly every year [42]. Its incidence is particularly high in western countries [43] where it is the most common malignancy and the second leading cause of death in men. In 2018, in the USA alone, the projected estimate is 29,430 deaths, 164,690 new cases [44] with an annual cost of treatment amounting to 12 billion dollars [45]. Lower incidence is observed in Asian countries; it is increasing in developed countries in South America, the Caribbean and sub-Saharan Africa [46]. These variations in incidence have been attributed, on the one hand, to diet, genetics,
lifestyle, and environment and, on the other hand, to the availability of the prostate-specific antigen (PSA) screening test [43,47]. However, the PSA test lacks precision as elevated PSA levels are also associated with benign prostate lesions [48,49]. PCa is a highly heterogenous and multifocal disease ranging from relatively harmless, indolent disease to metastatic and lethal disease [50]. The biological diversity of PCa together with the development of resistance to androgen depleton therapies poses significant challenges in the clinic [51,52].

Alternative splicing contributes to tumour heterogeneity and is exploited by cancer cells, allowing them to divert away from normal developmental pathways [53]. It is therefore an appropriate time to look at alternative splicing as a possible context in which to develop novel targeted therapies for the treatment of PCa. In the following sections, we describe how alternative splicing affects genes that are clearly linked to the aetiology of PCa.

2.2. Vascular Endothelial Growth Factor (VEGFA)

Vascular endothelial growth factor VEGFA (also known as VEGF) is a key regulator of angiogenesis, required for cancer growth and metastasis [54]. VEGFA acts as a mitogen on endothelial cells through the VEGFR1, VEGFR2 and VEGFR3 receptors [55,56]. VEGFA is a member of a growth factor family with a common VEGF homology domain; the family includes VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, VEGFF, and placental growth factors PIGF1 and -2 [57,58]. The conserved domain includes a cystine-knot structure formed by eight conserved cysteine residues [59].

The human VEGF genes generally contain seven exons; VEGFA has eight [60]. The VEGF genes are highly evolutionarily conserved [61]. At least 12 VEGFA isoforms are generated through alternative splicing of exons 6, 7 and 8 [62] giving rise to proteins with different heparin-binding properties [63]. VEGFA expresses both pro-angiogenic VEGF<sub>xxx</sub> and anti-angiogenic VEGF<sub>xxxb</sub>isoforms, where xxx is the number of amino acids. The isoforms are generated through use of alternative 3′ splice site in exon 8; the proximal splice site results in pro-angiogenic VEGF and distal exon 8 splice sites anti-angiogenic VEGF [64]. VEGFA expresses at least seven additional splice isoforms due to alternative splicing of exons 6 and 7 generating VEGF<sub>121</sub>, VEGF<sub>145</sub>, VEGF<sub>148</sub>, VEGF<sub>165</sub>, VEGF<sub>183</sub>, VEGF<sub>189</sub>, and VEGF<sub>206</sub>, all of which exhibit different biological properties [58]. The anti-angiogenic isoforms are generally downregulated and the pro-angiogenic isoforms upregulated in tumours [65]. One of the main anti-angiogenic isoforms downregulated in a variety of cancers including PCa is VEGF<sub>165b</sub> [66]. Curiously, both alternative splice sites in exon 8 are followed by six amino acids before the stop codon; pro-angiogenic VEGFA ends in CDKPRR whereas anti-angiogenic VEGFA ends in SLTRKD [67]. This subtle change affects its interaction with the receptor VEGFR2 resulting in weakened downstream signalling [68]. The regulation of alternative splicing of VEGFA into pro- and anti-angiogenic isoforms has yet to be fully understood [69]. However, recent studies have identified that three SR proteins, SRSF6 [64,70], SRSF1 activated by the splice factor kinase SRPK1 [71], and SRSF2 [72] all contribute to its regulation. Pro- and anti-angiogenic VEGFA splice isoforms are not the only VEGFA splice isoforms that are biologically significant in prostate cancer. For example, an increase in the VEGF<sub>121</sub>/VEGF<sub>165–189</sub> ratio in PC3 PCa cells results in a significant increase in angiogenesis in vivo, highlighting the importance of the VEGF<sub>121</sub> isoform in PCa, and demonstrating that the balance of splice isoforms affects prostate carcinogenesis [73].

2.3. The KLF6 Gene

The KLF6 gene product (Krüppel-like factor 6, also known as BCD1, COPEB, and ZF9) belongs to the family of Krüppel-like zinc finger transcription factors which consists of at least 24 members including Sp1-like (Sp1-8) and KFL-like factors (KFL1-16) [74]. It regulates a wide range of cellular processes including differentiation, proliferation, and apoptosis [75]. The gene is located on chromosome 10p15.2, a region deleted in about 55% of sporadic prostate adenocarcinomas [76]. It consists of four exons encoding a protein of 283 amino acids, including an N-terminus transactivation domain and three C-terminal C<sub>2</sub>—H<sub>2</sub> zinc fingers that form a DNA-binding domain [77]. KLF6 is a
tumour suppressor gene, named after the gap gene Krüppel from Drosophila melanogaster that causes a crippled phenotype when inactivated [78]. It is down-regulated in several types of cancer including PCa through a range of mechanisms including loss of heterozygosity (LOH), somatic mutations, or aberrant alternative splicing [79,80].

The alternative splicing of KLF6 results in the production of at least four splice isoforms [74]. One of the mutations found in PCa patients is a single nucleotide substitution in intron 1 that creates a novel binding site for the splicing factor SRSF5. This results in the use of two cryptic splice sites in exon 2 and enhances the expression of three alternative mRNA variants encoding for truncated KLF proteins; these are named Krüppel-like factor 6 splice variants 1, 2 and 3 (KLF6-SV1, SV2, and SV3). KLF6-SV does not have a zinc-finger DNA-binding domain but preserves most of the N-terminal domain [81]. KLF6-SV1 is formed by an alternative 5′ splice site in exon 3. A polymorphism of this isoform, IVS1 −27G>A, the IVS∆A allele, was shown to be associated with increased risk of PCa when 142 probands from a familial PCa registry were examined [82]. KLF6-SV1 is an antagonist of KLF6, and acting in a dominant-negative manner, it can promote increased cell growth. Knockdown of full length KLF6 increased tumour formation whereas knockdown of KLF-SV1 inhibited tumour formation [82]. Increased expression of KLF6-SV1 in tumours from men after prostatectomy is associated with lower survival rates and disease recurrence. When PCa cells are forced to overexpress this isoform in a mouse model, the mice are more susceptible to develop multi-organ metastases [83]. Increased expression of KLF6-SV1 is dependent on the Ras/PI3-K/Akt cell signalling pathway associated with increased cell proliferation and survival [84]. Together these findings suggest that the expression of the KLF6-SV1 isoform can promote metastatic phenotypes, and could be considered a target for therapy. The example also illustrates the point that a tumour suppressor gene can in fact acquire the properties of an oncogene, depending on how it is alternatively spliced.

2.4. The BCL2L1 Gene

The BCL2L1 (BCL2-like 1) gene, commonly referred to as BCLX, is a member of the BCL-2 gene family. The BCL-2 family encodes part of the core of the apoptotic machinery and is conserved from the nematode Caenorhabditis elegans to mammals [85]. Apoptosis is a highly regulated process in development, and it is critical for the development and progression of cancer [86]. The BCL-2 family is composed of three groups; anti-apoptotic proteins, pro-apoptotic effectors and pro-apoptotic activators. They share at least one out of four conserved BCL-2 homology domains (BH1-4) [87]. BCL2L1 has three exons and expresses several isoforms by alternative splicing with opposing functions, notably BCL-xL (B cell lymphoma extra-long) and BCL-xS (B cell lymphoma extra-small). The isoforms arise from alternative 5′ splice sites in exon 2. When the proximal splice site is selected, the BCL-xL isoform is expressed, whereas the BCL-xS isoform is expressed from the distal splice site [88].

The alternative splicing of BCL2L1 is known to be regulated by several splice factors. The pro-apoptotic isoform BCL-xS is promoted by hnRNP H and F [89], SAM68 [90], RBM25 [91], and RBM11 [92]. In contrast BCL-xL is promoted by SRSF1 [93], SRSF9 [94], and SAP155 [95]. In PCa cells, treatment with the drug calyculin A blocks emetine-induced BCL-xL expression through inhibition of the protein phosphatases PP1 and PP2A, phosphatases that are known to dephosphorylate SR protein splice factors [96]. BCL-xS is down-regulated in many types of cancer including prostate cancer [97]. BCL-xL is associated with hormone refractory phenotype in PCa [98] and contributes to resistance to chemotherapy [99]. In contrast, BCL-xS inhibits cell survival [100] and the shift from BCL-xL to BCL-xS expression induces apoptosis in PC3 and MCF-7 cells [86]. There is therefore interest in developing therapeutic tools that alter the balance of BCL2L1 splice isoforms in tumour cells to promote apoptosis.

2.5. The ERG Gene

ERG (V-Ets avian erythroblastosis virus E26 oncogene homolog) is a member of the ETS (E26 transformation-specific) transcription factor family, one of the largest families of transcriptional regulators consisting of at least 27 members, subdivided into five subfamilies [101]. All ETS
transcription factors contain a conserved ETS DNA-binding domain, consisting of 85 amino acids that recognize a core GGAA/T sequence [101]. ERG is expressed at low levels in normal prostate epithelial cells [102] and plays a key role in regulating a variety of cellular pathways such as cell proliferation, inflammation, apoptosis, and bone formation [103]. Strikingly, the ERG gene is highly expressed in more than 60% of patients with aggressive PCa [104].

ERG expression is generally activated through a 3 Mb deletion in chromosome 21 resulting in the fusion of the promoter of the androgen-regulated, prostate specific transmembrane serine protease TMPRSS2 gene with the coding region of ERG, generating an androgen-responsive fusion oncoprotein [105]. Prostate cancer cells positive for the fusion show increased ERG expression in response to androgens due to the TMPRSS2 promoter [106]. This fusion is the most common genetic lesion associated with disease mortality [107]. TMPRSS2 can also fuse with the ETV1 and ETV4 genes (also members of the ETS family of transcription factors), but the fusion with ERG is the most prevalent, detected in ~50% of patients [108,109]. The TMPRSS2-ERG fusion is also associated with increased tumour growth and metastasis [110] and correlates with PSA recurrence and seminal vesicle invasion [111].

The ERG gene consists of 17 exons and expresses several splice isoforms of which at least five are translated; ERG-1, ERG-2, ERG-3, ERG-4, and ERG-5 [112,113]. TMPRSS2-ERG fusions express several fusion transcripts depending on the precise site of fusion, causing additional heterogeneity [114]. Recent evidence has underlined the biological relevance of cassette exon 7b of ERG. This exon encodes, in frame, 24 amino-acids that are added to the transcription activation domain in the middle of the protein. Rates of exon 7b inclusion increase in later stages of PCa, suggesting that it enhances ERG’s oncogenic potential [115], presumably by altering the effect of ERG on its target genes. Therapies could be designed that target, specifically, ERG’s cassette exon 7b.

2.6. The Androgen Receptor (AR)

The normal development and maintenance of the prostate is dependent on androgens whose production is regulated by the hypothalamic-pituitary gonadal through the androgen receptor (AR, also known as DHTR or NR3C4) [116]. AR is a 110 kDa member of the steroid receptor transcription factor family which includes the estrogen receptor-α (ERα), estrogen receptor-β (ERβ), and progesterone receptor (PR) [53]. Men express one copy of the AR gene located at Xq11-12. The gene has eight exons and the protein is 919 amino acids long with three major functional domains. These are the N-terminal domain, the DNA-binding domain and the ligand-binding domain each with a vital role in AR activity [117,118]. Alterations in AR transcripts including insertions of cryptic exons downstream of the coding sequences [119] or exon skipping [120] disrupt the open reading frame, leading to the expression of truncated proteins that are not androgen dependent. Reactivation of AR signalling contributes to castration-resistant PCa [121]. There is still a degree controversy in relation to the association between AR activation and disease progression; some studies suggest that high AR expression increases tumour grade and stage leading to lower recurrence-free survival [122], whereas other studies associate decreased AR expression with tumour progression [123]. These discrepancies could be explained by the fact that it is not just overall expression of AR that matters, but also its alternative splicing.

There are at least 22 splice variants of AR [124] with AR-V7 and ARV567es the most commonly studied; of these, AR-V7 has been detected in the clinic [125]. Both splice variants lack the C-terminal ligand-binding domain; they are constitutively active and therefore resistant to traditional androgen deprivation therapy [126]. AR-V7 mRNA arises from an alternative 3’ splice site next to a cryptic exon 3B [127]. The detection of AR-V7 transcripts in circulating tumour cells of 62 men with progressive, metastatic castration-resistant PCa was associated with resistance to the AR inhibitors abiraterone and enzalutamide [128]. The splice factors U2AF65 and SRSF1 have been found to play a critical role in mediating AR-V7 expression [129].
AR\textsuperscript{V567es} arises from exon 5 to 7 skipping causing an early stop codon after the first 29 nucleotides of exon 8 [130]. AR\textsuperscript{V567es} has also been found to activate androgen-responsive genes such as KLK3, TMPRSS2, and NKKX3.1 in a hormone-independent manner when ectopically expressed in LNCaP cells [131]. Using a probasin promoter driven AR\textsuperscript{V567es} transgenic mouse, it was found that expression of AR\textsuperscript{V567es} in prostate leads to epithelial hyperplasia after 16 weeks, and invasive adenocarcinoma by year one in the experimental model. However, the precise role of the AR\textsuperscript{V567es} in normal prostate growth and castration-resistant PCa is still unclear [132].

Additional splice variants of AR have been described. One was identified by RACE (rapid amplification of cDNA ends) in CWR-R1 cells and named AR8. Its expression is highest in cells derived from castration-resistant tumours [133]. AR8 lacks a DNA-binding domain and localizes to the plasma membrane. Overexpression of AR8 promotes the association of Src and AR with the EGF receptor following EGF treatment. Another study described AR45, an isoform that lacks exon 1. Its overexpression decreases the proliferation of androgen-dependent LNCaP cells through the formation of AR-AR45 heterodimers, presumably by inhibiting the activity of full length AR [134].

In summary there are several, functionally distinct AR splice variants that contribute to androgen resistance mechanisms. It is therefore imperative to develop novel therapies that modify AR alternative splicing.

3. Modulation of Splicing for Therapeutic Benefit

Clinically significant splice isoforms often exhibit unique biological properties and can be targeted by pharmacological agents directly, or through targeting the splice factors that regulate their expression [135]. To illustrate this point, small molecular inhibitors of the SRPK1 splice factor kinase that phosphorylates the oncogenic splice factor SRSF1 can switch VEGFA splicing in favour of the anti-angiogenic isoforms in PCa cells [71]. SRPK1 inhibitors decrease tumour growth in a PCa mouse model in vivo providing strong evidence that they could be used therapeutically for treating PCa [72,136,137]. SPHINX is the latest generation SRPK1 inhibitor; it exhibits anti-tumour effects after repetitive intraperitoneal administration in a mouse model of orthotopic PCa [136]. The inhibition of SRPK1 brings benefits to other pathologies that involve abnormal angiogenesis. For example, a single dose of an earlier SRPK1 inhibitor, SRPIN340, significantly inhibits angiogenesis and increases normal vascularization in a mouse model of retinal neovascularization [72].

Small molecule inhibitors can also be used to alter the expression of AR splice isoforms through the inhibition of HSP90, a protein required for nuclear translocation of full-length AR in response to hormone. The first HSP90 inhibitor in clinical trials is alvespimycin [138]; it produces a good response in castrate-refractory PCa, and a stable response in patients with melanoma, chondrosarcoma, and renal cancer [139]. A second-generation HSP90 inhibitor called onalespib inhibits more than 500 splice isoforms including AR splice isoforms. In particular, onalespib was found to reduce the levels of both full length AR and AR-V7 in PCa cell lines in a concentration and time-dependent manner; it also reduced tumour growth in AR-V7 expressing 22Rv1 tumour xenografts [140]. However, the effect of HSP90 inhibition on the expression of AR splice isoforms is not yet entirely clear. Treatment with the second-generation HSP90 inhibitor luminespib increased AR-V7 expression in VCaP cells [141] whereas geldanamycin did not affect AR-V7 levels in 22Rv1 cells [142].

Another approach is the use of splice-switching oligonucleotides (SSOs). SSOs are short (15–25 bases in length), synthetic, antisense, modified nucleic acids that target exon-intron junctions or regulatory exonic and intronic sequences [143]. Their binding leads to the blocking of the RNA–RNA base-pairing or protein–RNA binding interactions that occur between components of the splicing machinery and the pre-mRNA [144]. SSOs have been used to modify splicing of BCL2L1, disrupting tumour growth in vivo by targeting the 5′ splice site of exon 2 of BCL2L1 pre-mRNA. This led to decreased expression of Bcl-xL and an increased expression of Bcl-xS splice isoform, inducing apoptosis in breast and PCa cells and reducing the tumour burden in vivo [145]. Another study found that the Bcl-xS
isoform, induced by SSOs, sensitized the cancer cells to treatment with ultraviolet, γ-irradiation and chemotherapeutic drugs [99].

Small interference RNAs (siRNAs) have been widely used to target splice variants and counteract their oncogenic activities. SiRNAs have been used to target specific AR exons, for example exon 1 in human prostate carcinoma 22Rv1 cells reduced cell proliferation [146]. SiRNA-mediated knockdown of AR isoforms that lack the C-terminal hormone binding domain suppressed androgen-independent cell proliferation, and induced G1 cell-cycle arrest and apoptosis; similar results were obtained through treatment with the antibiotic nigericin, known to act at a post-transcriptional level on AR expression [147].

Figure 1 summarizes different approaches to altering splicing in vivo. Splice factor kinases [71,136], splice factors [148], or even spliceosome components [149] can be targeted directly. RNA interference-based methods [150,151] and SSOs [86,152] have been successfully used to target specific splice isoforms at the RNA level. It seems highly likely that prostate cancer patients will benefit in the future from therapies directed at altering splicing of cancer-associated genes. The challenge will be to improve the stability, specificity, and delivery of modifiers of splicing to tumour sites, while minimising side-effects [152].

![Figure 1. Different approaches to the in vivo modification of splicing of cancer-specific isoforms.](image-url)

**Figure 1.** Different approaches to the in vivo modification of splicing of cancer-specific isoforms. Growth stimulatory signals that activate splice factor kinases through AKT or splice factors directly through ERK can be inhibited; splice factor kinases, splice factors or components of the spliceosome can also be targeted directly. At the RNA level, pre-mRNA splicing can be modified with splice switching oligonucleotides (SSOs), and specific mRNA isoforms can be targeted with siRNAs. At the protein level, drugs can also be targeted at specific isoforms.

4. Conclusions

It is abundantly clear that alternative splicing is vital for normal gene regulation, and that aberrant splicing is involved in many types of cancer, including prostate cancer. Therefore understanding the regulation of alternative splicing can provide new contexts for the development of novel therapeutic strategies. A number of cancer specific splice variants have been identified and discussed in this article, including VEGFA, KLF6, BCL2L2, ERG, and AR. Novel therapeutic strategies including the use of SSOs to alter the balance of pro- and anti-apoptotic BCL2L2 isoforms, siRNAs that target specific AR exons,
small molecule inhibitors that block AR-mediated signalling, or small molecules that inhibit splice factor kinases, have all shown promise. There is a pressing need to expand research into alternative splicing not just in the context prostate cancer, but in the context of many other important diseases.

**Acknowledgments:** Ladomery’s research is currently supported by a grant from Prostate Cancer UK, RIA-030-015.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- BPS: branchpoint sequence
- ESE: exonic splice enhancer
- ESS: exonic splice silencer
- ISE: intronic splice enhancer
- ISS: intronic splice silencer
- hnRNP: heterogenous ribonucleoprotein
- RACE: rapid amplification of cDNA ends
- snRNP: small nuclear ribonucleoprotein
- SR protein: serine/arginine-rich splice factor
- SSO: splice-switching oligonucleotide
- PCa: prostate cancer

**References**

1. Berget, S.M.; Moore, C.; Sharp, P.A. Spliced segments at the 5′ terminus of adenovirus 2 late mRNA. *Proc. Natl. Acad. Sci. USA* 1977, 74, 3171–3175. [CrossRef] [PubMed]
2. Chow, L.T.; Gelasin, R.E.; Broker, T.R.; Roberts, R.J. An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA. *Cell* 1977, 12, 1–8. [CrossRef]
3. Fica, S.M.; Tuttle, N.; Novak, T.; Li, N.S.; Lu, J.; Koodathingal, P; Dai, Q.; Staley, J.P.; Piccirilli, J.A. RNA catalyses nuclear pre-mRNA splicing. *Nature* 2013, 503, 229–234. [CrossRef] [PubMed]
4. Chen, M.; Manley, J.L. Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. *Nat. Rev. Mol. Cell Biol.* 2009, 10, 741–754. [CrossRef] [PubMed]
5. Smith, C.W.J. *Alternative Splicing in the Postgenomic Era*; Blencowe, B.J., Graveley, B.R., Eds.; Springer: New York, NY, USA, 2007; Volume XXIV, ISBN 978-0-387-77373-5.
6. Matlin, A.J.; Clark, F.; Smith, C.W. Understanding alternative splicing: Towards a cellular code. *Nat. Rev. Mol. Cell Biol.* 2005, 6, 386–398. [CrossRef] [PubMed]
7. Black, D.L. Mechanisms of alternative pre-messenger RNA splicing. *Annu. Rev. Biochem.* 2003, 72, 291–336. [CrossRef] [PubMed]
8. Graveley, B.R. Sorting out the complexity of SR protein functions. *RNA* 2000, 6, 1197–1211. [CrossRef] [PubMed]
9. Nilsen, T.W.; Graveley, B.R. Expansion of the eukaryotic proteome by alternative splicing. *Nature* 2010, 463, 457–463. [CrossRef] [PubMed]
10. Ghigna, C.; Giordano, S.; Shen, H.; Benvenuto, F.; Castiglioni, F.; Comoglio, P.M.; Green, M.R.; Riva, S.; Biamonti, G. Cell motility is controlled by SF2/ASF through alternative splicing of the *Ron* proto-oncogene. *Mol. Cell* 2005, 20, 881–890. [CrossRef] [PubMed]
11. Pandit, S.; Zhou, Y.; Shiue, L.; Coutinho-Mansfield, G.; Li, H.; Qiu, J.; Huang, J.; Yeo, G.W.; Ares, M., Jr.; Fu, X.D. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. *Mol. Cell* 2013, 50, 223–235. [CrossRef] [PubMed]
12. Caceres, J.F.; Kornblith, A.R. Alternative splicing: Multiple control mechanisms and involvement in human disease. *Trends Genet.* 2002, 18, 186–193. [CrossRef]
13. Fu, X.D.; Ares, M., Jr. Context-dependent control of alternative splicing by RNA-binding proteins. *Nat. Rev. Genet.* 2014, 15, 689–701. [CrossRef] [PubMed]
14. Zhu, J.; Mayeda, A.; Krainer, A.R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. *Mol. Cell* 2001, 8, 1351–1361. [CrossRef]
15. Velazquez-Dones, A.; Hagopian, J.C.; Ma, C.T.; Zhong, X.Y.; Zhou, H.; Ghosh, G.; Fu, X.D.; Adams, J.A. Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. *J. Biol. Chem.* **2005**, *280*, 41761–41768. [CrossRef] [PubMed]

16. Xiang, S.; Gapsy, V.; Kim, H.Y.; Bessonov, S.; Hsiao, H.H.; Mohlmann, S.; Klaukien, V.; Ficner, R.; Becker, S.; Urlaub, H.; et al. Phosphorylation drives a dynamic switch in serine/arginine rich proteins. *Structure* **2013**, *21*, 2162–2174. [CrossRef] [PubMed]

17. Patel, N.A.; Kaneko, S.; Apostolatos, H.S.; Bae, S.S.; Watson, J.E.; Davidowitz, K.; Chappell, D.S.; Birmbaum, M.J.; Cheng, J.Q.; Cooper, D.R. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase C betaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. *J. Biol. Chem.* **2005**, *280*, 14302–14309. [CrossRef] [PubMed]

18. Blaustein, M.; Pelisch, F.; Tanos, T.; Muñoz, M.J.; Wengier, D.; Quadranza, L.; Sanford, J.R.; Muschietti, J.P.; Kornblüth, A.R.; Cáceres, J.F.; et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. *Nat. Struct. Mol. Biol.* **2005**, *12*, 1037–1044. [CrossRef] [PubMed]

19. Aranda, S.; Laguna, A.; de la Luna, S. DYRK family of protein kinases: Evolutionary relationships, biochemical properties, and functional roles. *FASEB J.* **2011**, *25*, 449–462. [CrossRef] [PubMed]

20. De Graaf, K.; Hekerman, P.; Spelten, O.; Herrmann, A.; Packman, L.C.; Bussow, K.; Muller-Newen, G.; Becker, W. Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain: Phosphorylation by DYRK1A and colocalization with splicing factors. *J. Biol. Chem.* **2004**, *279*, 4612–4624. [CrossRef] [PubMed]

21. Aubol, B.E.; Wu, G.; Keshwani, M.M.; Movassat, M.; Fattet, L.; Hertel, K.J.; Fu, X.D.; Adams, J.A. Release of SR proteins from CLK1 by SRPK1: A symbiotic kinase system for phosphorylation control of pre-mRNA splicing. *Cell Mol. Biol.* **2016**, *63*, 218–222. [CrossRef] [PubMed]

22. Zhong, X.Y.; Ding, J.H.; Adams, J.A.; Ghosh, G.; Fu, X.D. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. *Genes Dev.* **2009**, *23*, 482–495. [CrossRef] [PubMed]

23. Aubol, B.E.; Chakrabarti, S.; Ngo, J.; Shaffer, J.; Nolen, B.; Fu, X.D.; Ghosh, G.; Adams, J.A. Processive phosphorylation of alternative splicing factor/splicing factor 2. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 12601–12606. [CrossRef] [PubMed]

24. Novoyatleva, T.; Heinrich, B.; Tang, Y.; Benderska, N.; Butchbach, M.E.; Lorson, C.L.; Lorson, M.A.; Ben-Dov, C.; Fehlbaum, P.; Bracco, L.; et al. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. *Hum. Mol. Gen.* **2008**, *17*, 52–70. [CrossRef] [PubMed]

25. Sanford, J.R.; Gray, N.K.; Beckman, K.; Cáceres, J.F. A novel role for shuttling SR proteins in mRNA translation. *Genes Dev.* **2004**, *18*, 755–768. [CrossRef] [PubMed]

26. Ni, J.Z.; grate, L.; Donohue, J.P.; Preston, C.; Nobida, N.; O’Brien, G.; Shuie, L.; Clark, T.A.; Blume, J.E.; Ares, M., Jr. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. *Genes Dev.* **2007**, *21*, 708–718. [CrossRef] [PubMed]

27. Maniatis, T.; Reed, R. An extensive network of coupling among gene expression machines. *Nature* **2002**, *416*, 499–506. [CrossRef] [PubMed]

28. Keren, H.; Lev-Maor, G.; Ast, G. Alternative splicing and evolution: Diversification, exon definition and function. *Nat. Rev. Genet.* **2010**, *11*, 345–355. [CrossRef] [PubMed]

29. Gilbert, W. Why genes in pieces? *Nature* **1978**, 271, 501. [CrossRef] [PubMed]

30. Schmucker, D.; Clemens, J.; Shu, H.; Worby, C.; Xiao, J.; Muda, M.; Dixon, J.; Zipursky, S.L. *Drosophila* Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. *Cell* **2000**, *101*, 671–684. [CrossRef]

31. Tabuchi, K.; Südhof, T.C. Structure and evolution of neurexin genes: Insight into the mechanism of alternative splicing. *Genomics* **2002**, *79*, 849–859. [CrossRef] [PubMed]

32. Loria, P.M.; Duke, A.; Rand, J.B.; Hobert, O. Two neuronal, nuclear-localized RNA binding proteins involved in synaptic transmission. *Curr. Biol.* **2003**, *13*, 1317–1323. [CrossRef]

33. Hodgkin, J.; Zellan, J.D.; Albertson, D.G. Identification of a candidate primary sex determination locus, fox-1, on the X chromosome of *Caenorhabditis elegans*. *Development* **1994**, *120*, 3681–3689. [PubMed]

34. Zhou, Y.; Zhou, C.; Ye, L.; Dong, J.; Xu, H.; Cai, L.; Zhang, L.; Wei, L. Database and analyses of known alternatively spliced genes in plants. *Genomics* **2003**, *82*, 584–595. [CrossRef]

35. McKibbin, R.S.; Wilkinson, M.D.; Bailey, P.C.; Flintham, J.E.; Andrew, L.M.; Lazzeri, P.A.; Gale, M.D.; Lenton, J.R.; Holdsworth, M.J. Transcripts of Vp-1 homeologues are misspliced in modern wheat and ancestral species. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 10203–10208. [CrossRef] [PubMed]
36. Procissi, A.; Piazza, P.; Tonelli, C. A maize r1 gene is regulated post-transcriptionally by differential splicing of its leader. *Plant Mol. Biol.* 2002, 49, 239–248. [CrossRef] [PubMed]

37. Montag, K.; Salamini, F.; Thompson, R.D. ZEMa, a member of a novel group of MADS box genes, is alternatively spliced in maize endosperm. *Nucleic Acids Res.* 1995, 23, 2168–2177. [CrossRef] [PubMed]

38. Blencowe, B.J. Alternative splicing: New insights from global analyses. *Cell* 2006, 126, 37–47. [CrossRef] [PubMed]

39. Kim, E.; Mage, A.; Ast, G. Different levels of alternative splicing among eukaryotes. *Nucleic Acids Res.* 2007, 35, 125–131. [CrossRef] [PubMed]

40. Wahl, M.C.; Will, C.L.; Lührmann, R. The spliceosome: Design principles of a dynamic RNP machine. *Cell* 2009, 36, 701–718. [CrossRef] [PubMed]

41. Venables, J.P.; Klinck, R.; Koh, C.; Gervais-Bird, J.; Bramard, A.; Inkel, L.; Durand, M.; Couture, S.; Froehlich, U.; Lapointe, E.; et al. Cancer-associated regulation of alternative splicing. *Nat. Struct. Mol. Biol.* 2009, 16, 670–676. [CrossRef] [PubMed]

42. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur. J. Cancer* 2010, 46, 735–781. [CrossRef] [PubMed]

43. Baade, P.D.; Youliden, D.R.; Knjajcki, L.J. International epidemiology of prostate cancer: Geographical distribution and secular trends. *Mol. Nutr. Food Res.* 2009, 53, 171–184. [CrossRef] [PubMed]

44. American Cancer Society. Available online: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html (accessed on 24 April 2018).

45. Silberstein, J.L.; Pal, S.K.; Lewis, B.; Sartor, O. Current clinical challenges in prostate cancer. *Transl. Androl. Urol.* 2013, 2, 122–136. [PubMed]

46. Center, M.M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley, O.; Bray, F. International variation in prostate cancer incidence and mortality rates. *Eur. Urol.* 2012, 61, 1079–1092. [CrossRef] [PubMed]

47. Zhang, L.; Yang, B.X.; Zhang, H.T.; Wang, J.G.; Wang, H.L.; Zhao, X.J. Prostate cancer: An emerging threat to the health of aging men in Asia. *Asian J. Androl.* 2011, 13, 574–578. [CrossRef] [PubMed]

48. Ilic, D.; O’Connor, D.; Green, S.; Wilt, T.J. Screening for prostate cancer: An updated Cochrane systematic review. *BJU Int.* 2011, 107, 882–891. [CrossRef] [PubMed]

49. Loeb, S.; Catalona, W.J. Prostate-specific antigen screening: Pro. *Curr. Opin. Urol.* 2010, 20, 185–188. [CrossRef] [PubMed]

50. Lapuk, A.V.; Volik, S.V.; Wang, Y.; Collins, C.C. The role of mRNA splicing in prostate cancer. *Asian J. Androl.* 2014, 16, 515–521. [CrossRef] [PubMed]

51. Boudadi, K.; Antonarakis, E.S. Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer. *Clin. Med. Insight Oncol.* 2016, 10, 1–9. [CrossRef]

52. Cyll, K.; Ersvær, E.; Vlatkovic, L.; Pradhan, M.; Kildal, W.; Kjaer, M.A.; Kleppe, A.; Hveem, T.S.; Carlsen, B.; Gill, S.; et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. *Br. J. Cancer* 2017, 117, 367–375. [CrossRef] [PubMed]

53. Delhm, S.M.; Tindall, D.J. Alternatively spliced androgen receptor variants. *Endocr. Relat. Cancer* 2011, 18, 183–196. [CrossRef] [PubMed]

54. Niu, G.; Chen, X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. *Curr. Drug Targets* 2010, 11, 1000–1017. [CrossRef] [PubMed]

55. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojro, M. Angiogenesis in cancer. *Vasc. Health Risk Manag.* 2006, 2, 213–219. [CrossRef] [PubMed]

56. Shibuya, M. Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E. *Cancer Sci.* 2003, 94, 751–756. [CrossRef] [PubMed]

57. Li, X.; Eriksson, U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. *Int. J. Biochem. Cell Biol.* 2001, 33, 421–426. [CrossRef]

58. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. *Endocr. Rev.* 2004, 25, 581–611. [CrossRef] [PubMed]

59. Vitt, U.A.; Hsu, S.Y.; Hsueh, A.J. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. *Mol. Endocrinol.* 2001, 15, 681–694. [CrossRef] [PubMed]

60. George, M.I.; Tutton, M.G.; Janssen, F.; Arnaout, A.; Abulafi, A.M.; Eccles, S.A.; Swift, R.L. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. *Neoplasia* 2001, 3, 420–427. [CrossRef] [PubMed]

61. Claffey, K.P.; Senger, D.R.; Spiegelman, B.M. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. *Biochim. Biophys. Acta* 1995, 1246, 1–9. [CrossRef]
62. Perrin, R.M.; Konopatskaya, O.; Qiu, Y.; Harper, S.; Bates, D.O.; Churchill, A.J. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia* **2005**, *48*, 2422–2427. [CrossRef] [PubMed]

63. Houck, K.A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D.W. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol. Endocrinol.* **1991**, *5*, 1806–1814. [CrossRef] [PubMed]

64. Nowak, D.G.; Woolard, J.; Amin, E.M.; Konopatskaya, O.; Saleem, M.A.; Churchill, A.J.; Ladomery, M.R.; Harper, S.J.; Bates, D.O. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. *J. Cell Sci.* **2008**, *121*, 3487–3495. [CrossRef] [PubMed]

65. Takahashi, H.; Shibuya, M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin. Sci. (Lond.)* **2005**, *109*, 227–241. [CrossRef] [PubMed]

66. Woolard, J.; Wang, W.Y.; Bevan, H.S.; Cui, T.G.; Sugiono, M.; Bieker, J.J. Krüppel-like factors: Three fingers in many pies.

67. Bates, D.O.; Cui, T.G.; Doughty, J.M.; Winkler, M.; Sugiono, M.; Shields, J.D.; Peat, D.; Gillatt, D.; Harper, S.J. VEGF165B, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. *Cancer Res.* **2004**, *64*, 7822–7838. [CrossRef] [PubMed]

68. Difeo, A.; Martignetti, J.A.; Narla, G. The role of KLF6 and its splice variants in cancer therapy.

69. Schumacher, V.A.; Jeruschke, S.; Eitner, F.; Becker, J.U.; Pitschke, G.; Ince, Y.; Miner, J.H.; Leuschner, I.; Engers, R.; Everding, A.S.; et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. *J. Am. Soc. Nephrol.* **2007**, *18*, 719–729. [CrossRef] [PubMed]

70. Manetti, M.; Guiducci, S.; Romano, E.; Ceccarelli, C.; Bellando-Randone, S.; Conforti, M.L.; Ibba-Manneschi, L.; Matucci-Cerinic, M. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. *Circ. Res.* **2011**, *109*, e14–e26. [CrossRef] [PubMed]

71. Amin, E.M.; Oltean, S.; Hua, J.; Gammons, M.V.; Hamdollah-Zadeh, M.; Welsh, G.I.; Cheung, M.K.; Ni, L.; Kase, S.; Rennel, E.S.; et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. *Cancer Cell* **2011**, *20*, 768–780. [CrossRef] [PubMed]

72. Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J.L.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymir, B. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. *Onco gene* **2010**, *29*, 5392–5403. [CrossRef] [PubMed]

73. Catena, R.; Muniz-Medina, V.; Moralejo, B.; Javierre, B.; Best, C.J.; Emmert-Buck, M.R.; Green, J.E.; Baker, C.C.; Calvo, A. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. *Onco gene* **2010**, *29*, 768–780. [CrossRef] [PubMed]

74. Schumacher, V.A.; Jeruschke, S.; Eitner, F.; Becker, J.U.; Pitschke, G.; Ince, Y.; Miner, J.H.; Leuschner, I.; Engers, R.; Everding, A.S.; et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. *J. Am. Soc. Nephrol.* **2007**, *18*, 719–729. [CrossRef] [PubMed]

75. Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J.L.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymir, B. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. *Onco gene* **2010**, *29*, 5392–5403. [CrossRef] [PubMed]

76. Nowak, D.G.; Woolard, J.; Amin, E.M.; Konopatskaya, O.; Saleem, M.A.; Churchill, A.J.; Ladomery, M.R.; Harper, S.J.; Bates, D.O. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. *J. Cell Sci.* **2008**, *121*, 3487–3495. [CrossRef] [PubMed]

77. Perrin, R.M.; Konopatskaya, O.; Qiu, Y.; Harper, S.; Bates, D.O.; Churchill, A.J. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia* **2005**, *48*, 2422–2427. [CrossRef] [PubMed]

78. Gloor, H. Schadigungsmuster eines Letalfaktors (Kr) von *Drosophila melanogaster*. *Arch. Klaus-Stift. VererbForsch.* **1950**, 25, 38–44.

79. Narla, G.; Heath, K.E.; Reeves, H.L.; Li, D.; Giono, L.E.; Kimmelman, A.C.; Glucksman, M.J.; Narla, J.; Eng, F.J.; Chan, A.M.; et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. *Science* **2001**, *294*, 2563–2566. [CrossRef] [PubMed]
80. Chen, H.; Hyrytinenn, E.R.; Sun, X.; Helin, H.J.; Koivisto, P.A.; Frierson, H.F.J.R.; Vessella, R.L.; Dong, J.T. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. *Am. J. Pathol.* 2003, 163, 1349–1354. [CrossRef]

81. Liu, X.; Gomez-Pinillos, A.; Loder, C.; Carrillo-de Santa Pau, E.; Qiao, R.; Unger, P.D.; Kurek, R.; Oddoux, C.; Melamed, J.; et al. KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. *Am. J. Pathol.* 2012, 181, 1007–1016. [CrossRef] [PubMed]

82. Narla, G.; Difeo, A.; Reeves, H.L.; Schaid, D.J.; Hirshfeld, J.; Hod, E.; Katz, A.; Isaacs, W.B.; Hebbring, S.; Komiy, A.; et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. *Cancer Res.* 2005, 65, 1213–1222. [CrossRef] [PubMed]

83. Narla, G.; Difeo, A.; Fernandez, Y.; Dhanasekaran, S.; Huang, F.; Sangodkar, J.; Hod, E.; Leake, D.; Friedman, S.I.; Hall, S.J.; et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. *J. Clin. Investig.* 2008, 118, 2711–2721. [CrossRef] [PubMed]

84. Yea, S.; Narla, G.; Zhao, X.; Garg, R.; Tal-Kremer, S.; Hod, E.; Villanueva, A.; Loke, J.; Tarocchi, M.; Akita, K.; et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. *Gastroenterology* 2008, 134, 1521–1531. [CrossRef] [PubMed]

85. Fuchs, Y.; Steller, H. Live to die another way: Modes of programmed cell death and the signals emanating from dying cells. *Nat. Rev. Mol. Cell Biol.* 2015, 16, 329–344. [CrossRef] [PubMed]

86. Mercatante, D.R.; Bortner, C.D.; Cedlowski, J.A.; Kole, R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells: Analysis of apoptosis and cell death. *J. Biol. Chem.* 2001, 276, 16411–16417. [CrossRef] [PubMed]

87. Czabotar, P.E.; Lessene, G.; Strasser, A.; Adams, J.M. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 49–63. [CrossRef] [PubMed]

88. Bielli, P.; Bordi, M.; di Biasio, V.; Sette, C. The RNA-binding protein Sam68 modulates the alternative splicing of the apoptotic mediator Bcl-x. *Mol. Cell. Biol.* 2008, 28, 5924–5936. [CrossRef] [PubMed]

89. Garneau, D.; Revil, T.; Fisette, J.F.; Chabot, B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. *J. Biol. Chem.* 2005, 280, 22641–22650. [CrossRef] [PubMed]

90. Paronetto, M.P.; Achsel, T.; Massiello, A.; Chalfant, C.E.; Sette, C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. *J. Cell Biol.* 2007, 176, 929–939. [CrossRef] [PubMed]

91. Zhou, A.; Ou, A.C.; Cho, A.; Benz, E.J.; Huang, S.C. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5′ splice site selection. *Mol. Cell. Biol.* 2008, 28, 5924–5936. [CrossRef] [PubMed]

92. Pedrotti, S.; Busà, R.; Compagnucci, C.; Sette, C. The RNA recognition motif protein RBM11 is a novel tissue-specific splicing regulator. *Nucleic Acids Res.* 2011, 40, 1021–1032. [CrossRef] [PubMed]

93. Moore, M.J.; Wang, Q.; Kennedy, C.J.; Silver, P.A. An alternative splicing network links cell-cycle control to apoptosis. *Cell* 2010, 142, 625–636. [CrossRef] [PubMed]

94. Cloutier, P.; Toutant, J.; Shkreta, L.; Goekjian, S.; Revil, T.; Chabot, B. Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. *J. Biol. Chem.* 2008, 283, 21315–21324. [CrossRef] [PubMed]

95. Massiello, A.; Roesser, J.R.; Chalfant, C.E. Sap155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5′ splice site selection of bcl-x pre-mRNA. *FASEB J.* 2006, 20, 1680–1682. [CrossRef] [PubMed]

96. Unge, K.B.; Yu, Q.; Zou, T.; Zhou, A.; Govitrapong, P.; Zhou, J. Emerine regulates the alternative splicing of Bcl-x through a protein phosphatase-1 dependent mechanism. *Chem. Biol.* 2007, 14, 1386–1392. [CrossRef] [PubMed]

97. David, C.J.; Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. *Genes Dev.* 2010, 24, 343–2364. [CrossRef] [PubMed]

98. Hoimes, C.J.; Kelly, W.K. Redefining hormone resistance in prostate cancer. *Ther. Adv. Med. Oncol.* 2010, 2, 107–123. [CrossRef] [PubMed]

99. Mercatante, D.R.; Mohler, J.L.; Kole, R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. *J. Biol. Chem.* 2002, 277, 49374–49382. [CrossRef] [PubMed]

100. Boise, L.H.; González-García, G.; Postema, C.E.; Ding, L.; Lindsten, T.; Turka, L.A.; Mao, X.; Nuñez, G.; Thompson, C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. *Cell* 1993, 74, 597–608. [CrossRef]
101. Watson, D.K.; Turner, D.P.; Scheiber, M.N.; Findlay, V.J.; Watson, P.M. ETS transcription factor expression and conversion during prostate and breast cancer progression. *Open Cancer J.* 2010, 3, 24–39. [CrossRef]

102. Sette, C. Alternative splicing programs in prostate cancer. *Int. J. Cell Biol.* 2013, 1–10. [CrossRef] [PubMed]

103. Seth, A.; Watson, D.K. ETS transcription factors and their emerging roles in human cancer. *Eur. J. Cancer* 2005, 41, 2462–2478. [CrossRef] [PubMed]

104. Petrovics, G.; Liu, A.; Shaheduzzaman, S.; Furusato, B.; Sun, C.; Chen, Y.; Nau, M.; Ravindranath, L.; Chen, Y.; Dobi, A.; et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. *Oncogene* 2005, 24, 3847–3852. [CrossRef] [PubMed]

105. Soller, M.J.; Isaksson, M.; Elfving, P.; Soller, W.; Lundgren, R.; Panagopoulos, I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. *Genes Chromosom. Cancer* 2006, 45, 717–719. [CrossRef] [PubMed]

106. Tomlins, S.A.; Laxman, B.; Varambally, S.; Cao, X.; Yu, J.; Helgeson, B.E.; Cao, Q.; Preßner, J.R.; Rubin, M.A.; Shah, R.B.; et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 2008, 10, 177–188. [CrossRef] [PubMed]

107. Demichelis, F.; Fall, K.; Perner, S.; André, O.; Schmidt, F.; Setlur, S.R.; Hoshida, Y.; Mosquera, J.M.; Pawitan, Y.; Lee, C.; et al. TMPRSS2/ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene* 2007, 26, 4596–4599. [CrossRef] [PubMed]

108. Kumar-Sinha, C.; Tomlins, S.A.; Chinnaiyan, A.M. Recurrent gene fusions in prostate cancer. *Nat. Rev. Cancer* 2008, 8, 497–511. [CrossRef] [PubMed]

109. Perner, S.; Demichelis, F.; Beroukhim, R.; Schmidt, F.H.; Mosquera, J.M.; Setlur, S.R.; Tchinda, J.; Tomlins, S.A.; Hofer, M.D.; Pienta, K.G.; et al. TMPRSS2-ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. *Cancer Res.* 2006, 66, 8337–8341. [CrossRef] [PubMed]

110. Shah, R.B.; Chinnaiyan, A.M. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: Significance and clinical implications. *Adv. Anatomi. Pathol.* 2009, 16, 145–153. [CrossRef] [PubMed]

111. Wang, J.; Cai, Y.; Yu, W.; Spencer, D.M.; Ittmann, M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. *Cancer Res.* 2008, 68, 8516–8524. [CrossRef] [PubMed]

112. Owczarek, C.M.; Portbury, K.J.; Hardy, M.P.; O’Leary, D.A.; Shibuya, K.; Shimizu, N.; Kola, I.; Hertzog, P.J. Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. *Gene* 2004, 324, 65–77. [CrossRef] [PubMed]

113. Hewett, P.W.; Nishi, K.; Daiti, E.L.; Clifford Murray, J. Selective expression of ERG isoforms in human endothelial cells. *Int. J. Biochem. Cell Biol.* 2001, 33, 347–355. [CrossRef]

114. Clark, J.; Merson, S.; Jhavar, S.; Flohr, P.; Edwards, S.; Foster, C.S.; Eeles, R.; Martin, F.L.; Phillips, D.H.; Crundwell, M.; et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. *Oncogene* 2007, 26, 2667–2673. [CrossRef] [PubMed]

115. Hagen, R.M.; Adamo, P.; Karamat, S.; Oxley, J.; Aning, J.J.; Gillatt, D.; Persad, R.; Ladomery, M.R.; Rhodes, A. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: Association with seminal vesicle invasion and biochemical recurrence. *Am. J. Clin. Pathol.* 2014, 142, 533–540. [CrossRef] [PubMed]

116. Debes, J.D.; Tindall, D.J. The role of androgens and the androgen receptor in prostate cancer. *Cancer Lett.* 2002, 187, 1–7. [CrossRef]

117. Tan, M.E.; Li, J.; Xu, E.; Melcher, K.; Yong, E.L. Androgen receptor: Structure, role in prostate cancer and drug discovery. *Acta Pharm. Sin.* 2015, 36, 3–23. [CrossRef] [PubMed]

118. Gao, W.; Bohl, C.E.; Dalton, J. Chemistry and structural biology of androgen receptor. *Chem. Rev.* 2005, 105, 3352–3370. [CrossRef] [PubMed]

119. Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B.; et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res.* 2009, 69, 16–22. [CrossRef] [PubMed]

120. Hu, R.; Isaacs, W.B.; Luo, J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. *Prostate* 2011, 71, 1656–1667. [CrossRef] [PubMed]

121. Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. *Oncogene* 2014, 33, 2815–2825. [CrossRef] [PubMed]
122. Mashhadi, R.; Pourmand, G.; Kosari, F.; Mehrsai, A.; Salem, S.; Pourmand, M.R.; Alatab, S.; Khonsari, M.; Heydari, F.; Beladi, L. Role of steroid hormone receptors in formation and progression of bladder carcinoma: A case-control study. *Urol. J.* 2014, 11, 1968–1973. [PubMed]

123. Tuygun, C.; Kankaya, D.; Imamoglu, A.; Sertcelik, A.; Zengin, K.; Oktay, M.; Sertcelik, N. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. *Urol. Oncol.* 2011, 29, 43–51. [CrossRef] [PubMed]

124. Lu, C.; Luo, J. Decoding the androgen receptor splice variants. *Transl. Androl. Urol.* 2013, 2, 178–186. [PubMed]

125. Hu, R.; Lu, C.; Mostaghel, E.A.; Yegnasubramanian, S.; Gurel, M.; Tannahill, C.; Edwards, J.; Isaacs, W.; Nelson, P.S.; Bluemn, E.; et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. *Cancer Res.* 2012, 72, 3457–3462. [CrossRef] [PubMed]

126. Lu, J.; van der Steen, T.; Tindall, D.J. Are androgen receptor variants a substitute for the full-length receptor? *Nat. Rev. Urol.* 2015, 12, 137–144. [CrossRef] [PubMed]

127. Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D.E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C.G.; et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. *Cancer Res.* 2009, 69, 2305–2313. [CrossRef] [PubMed]

128. Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roerer, J.C.; Chen, Y; Mohammad, T.A.; Chen, V.; Fedor, H.L.; et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N. Engl. J. Med.* 2014, 371, 1028–1038. [CrossRef] [PubMed]

129. Liu, L.L.; Xie, N.; Sun, S.; Plymate, S.; Mostaghel, E.; Dong, X. Mechanisms of the androgen receptor splicing in prostate cancer cells. *Oncogene* 2014, 33, 3140–3150. [CrossRef] [PubMed]

130. Clinicemalie, L.; Vanderschueren, D.; Boonen, S.; Claessens, F. The hinge region in androgen receptor control. *Mol. Cell. Endocrinol.* 2012, 358, 1–8. [CrossRef] [PubMed]

131. Sun, S.; Sprenger, C.C.; Vessella, R.L.; Haugk, K.; Soriano, K.; Mostaghel, E.A.; Page, S.T.; Coleman, I.M.; Nguyen, H.M.; Sun, H.; et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. *J. Clin. Investig.* 2010, 120, 2715–2730. [CrossRef] [PubMed]

132. Liu, G.; Sprenger, C.; Sun, S.; Soriano Epilepsia, K.; Haugk, K.; Zhang, X.; Colem, I.; Nelson, P.S.; Plymate, S. AR variant ARV567ES induces carcinogenesis in a novel transgenic mouse model of prostate cancer. *Neoplasia* 2013, 15, 1009–1017. [CrossRef] [PubMed]

133. Yang, X.; Guo, Z.; Sun, F.; Li, W.; Alfano, A.; Shimels, H.; Chen, M.; Brodie, A.M.; Chen, H.; Xiao, Z.; et al. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. *J. Biol. Chem.* 2011, 286, 36152–36160. [CrossRef] [PubMed]

134. Ahrens-Fath, I.; Politiz, O.; Geserick, C.; Haendler, B. Androgen receptor function is modulated by the tissue-specific AR45 variant. *FEBS J.* 2005, 272, 74–84. [CrossRef] [PubMed]

135. Bracco, L.; Kearsey, J. The relevance of alternative RNA splicing to pharmacogenomics. *Trends Biotechnol.* 2003, 21, 346–353. [CrossRef]

136. Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodoran, G.; Babaei-Jadidi, R.; Oxley, J.; Gillatt, D.A.; Ladomery, M.R.; Harper, S.J.; Bates, D.O.; et al. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. *Oncogene* 2015, 34, 4311–4319. [CrossRef] [PubMed]

137. Gammons, M.V.; Fedorov, O.; Ivison, D.; Du, C.; Clark, T.; Hopkins, C.; Hagiwara, M.; Dick, A.D.; Cox, R.; Harper, S.J.; et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. *Investig. Ophth. Vis. Sci.* 2013, 54, 6052–6062. [CrossRef] [PubMed]

138. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. *Nat. Rev. Cancer* 2010, 10, 537–549. [CrossRef] [PubMed]

139. Pacey, S.; Wilson, R.H.; Walton, M.; Eatock, M.M.; Hardcastle, A.; Zetterlund, A.; Arkenau, H.T.; Moreno-Farre, J.; Banerji, U.; Roels, B.; et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. *Clin. Cancer Res.* 2011, 17, 1561–1570. [CrossRef] [PubMed]

140. Ferraldeschi, R.; Welti, J.; Powers, M.V.; Yuan, W.; Smyth, T.; Seed, G.; Riisnaes, R.; Hedayat, S.; Wang, H.; Crespo, M.; et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. *Cancer Res.* 2016, 76, 2731–2742. [CrossRef] [PubMed]
141. Gillis, J.L.; Selt, L.A.; Centenera, M.M.; Townley, S.L.; Sun, S.; Plymate, S.R.; Tilley, W.D.; Butler, L.M. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 2013, 4, 691–704. [CrossRef] [PubMed]

142. Shafi, A.A.; Cox, M.B.; Weigel, N.L. Androgen receptor splice variants are resistant to inhibitors of HSP90 and FKBP52, which alter androgen receptor activity and expression. Steroids 2013, 78, 548–554. [CrossRef] [PubMed]

143. Mavrou, A.; Oltean, S. SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharm. Res. 2016, 107, 276–281. [CrossRef] [PubMed]

144. Havens, M.A.; Hastings, M.L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016, 44, 6549–6563. [CrossRef] [PubMed]

145. Bauman, J.A.; Li, S.D.; Yang, A.; Huang, L.; Kole, R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2016, 107, 276–281. [CrossRef] [PubMed]

146. Dehm, S.M.; Schmidt, L.J.; Heemers, H.V.; Vessella, R.I.; Tindall, D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68, 5469–5477. [CrossRef] [PubMed]

147. Mashima, T.; Okabe, S.; Seimiya, H. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Mol. Pharm. 2010, 78, 846–854. [CrossRef] [PubMed]

148. Esquela-Kerscher, A.; Slack, F.J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269. [CrossRef] [PubMed]

149. Soret, J.; Bakkour, N.; Maire, S.; Durand, S.; Zekri, L.; Gabut, M.; Fic, W.; Divita, G.; Rivalle, C.; Dauzonne, D.; et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc. Natl. Acad. Sci. USA 2005, 102, 8764–8769. [CrossRef] [PubMed]

150. Pawallek, A.; McElroy, S.; Samatov, T.; Mitchell, L.; Woodland, A.; Ryder, U.; Gray, D.; Lührmann, R.; Lamond, A.I. Identification of small molecule inhibitors of pre-mRNA splicing. J. Biol. Chem. 2015, 290, 6005. [CrossRef] [PubMed]

151. Kiermer, V. Focus on RNA interference. Nat. Methods 2006, 3, 669. [CrossRef]

152. Salton, M.; Misteli, T. Small molecule modulators of pre-mRNA splicing in cancer therapy. Trends Mol. Med. 2016, 22, 28–37. [CrossRef] [PubMed]